Faculty Profiles - FUJII Keiko

MISC - FUJII Keiko

Division display 61 - 80 of about 83 ／ All the affair displays >>

輸血当直における各業務過程の所要時間Turn-around Time(TAT)についての検討

小郷博昭, 浅野尚美, 池田亮, 閘結稀, 石川立則, 吉岡尚徳, 小林優人, 高木尚江, 藤井敬子, 藤井伸治, 大塚文男

日本輸血細胞治療学会誌 61 ( 6 ) 590 - 590 2015.12

末梢血幹細胞採取時の健常人ドナーにおけるクエン酸中毒発現、電解質異常についての解析

藤井敬子, 石川立則, 吉岡尚徳, 廻勇輔, 藤原英晃, 小林優人, 高木尚江, 閘結稀, 池田亮, 浅野尚美, 小郷博昭, 藤井伸治, 大塚文男

日本輸血細胞治療学会誌 61 ( 6 ) 593 - 593 2015.12

自家末梢血造血幹細胞移植の前処置において、抗がん剤投与量はBMIに応じて増減すべきか

谷勝真, 藤原英晃, 西森久和, 松岡賢市, 藤井伸治, 近藤英生, 前田嘉信, 谷本光音, 廻勇輔, 小林優人, 藤井敬子

臨床血液 56 ( 5 ) 537 - 537 2015.5

難治性Sweet病を合併したMDSに対して同種造血幹細胞移植を施行した1例

本倉恵美, 三道康永, 佐伯恭昌, 藤井伸治, 藤原英晃, 西森久和, 松岡賢市, 近藤英生, 前田嘉信, 谷本光音, 廻勇輔, 小林優人, 藤井敬子, 藤原暖, 土井裕子, 加持達弥, 岩月啓氏

臨床血液 56 ( 5 ) 538 - 538 2015.5

血液疾患患者におけるHLA適合血小板輸血後の有効性評価

藤井伸治, 小郷博昭, 小林優人, 藤井敬子, 近藤英生, 浅野尚美, 池田亮, 山川美和, 高木尚江, 平田康司

日本輸血細胞治療学会誌 61 ( 2 ) 258 - 258 2015.4

当院における70歳以上の高齢血液疾患患者に対する同種造血幹細胞移植

近藤正太郎, 前田嘉信, 松岡賢市, 品川克至, 藤井敬子, 藤井伸治, 近藤英生, 谷本光音

日本老年医学会雑誌 51 ( 3 ) 293 - 293 2014.5

DETECTION AND KINETICS OF DONOR-DERIVED ANTI-JRA IN AN UNRELATED BONE MARROW TRANSPLANTATION RECIPIENT: A CASE REPORT

Ikeda Toru, Ogo Hiroaki, Asano Naomi, Asada Noboru, Fujii Keiko, Fujii Nobuharu

JJTC 60 ( 3 ) 483 - 487 2014

Language：Japanese Publisher：The Japan Society of Transfusion Medicine and Cell Therapy

Jra is a frequently detected red blood cell antigen known as antigen 901005 according to the ISBT nomenclature. The frequency of Jr (a-) is 0.065% among the Japanese population. We herein report a case of a bone marrow transplantation (BMT) recipient in whom donor-derived anti-Jra was detected on day 15 after BMT. The recipient, a male patient in his fifties, had chronic myeloid leukemia in the second chronic phase after a lymphoid blast crisis. He was group A, D+, and Jr (a+) and had no other irregular antibodies. The donor, a female patient in her forties, was group A, D+, Jr (a-) and had anti-Jr (a) antibodies. A total of 6 units of randomly selected red cell concentrate (RCC) was transfused on days 9, 11, and 14 after BMT. The direct globulin test of the recipient was negative before transplantation; however, it changed to positive on day 12 after transplantation. The irregular antibody test result subsequently changed to positive, and anti-Jra was detected on day 15. Based on this result, we used Jr (a-) RCC for the next 16 units of RCC transfusion. Clinically, there were no hemolytic adverse effects. His direct globulin test and irregular antibody test became negative on days 39 and 53, respectively. Although the clinical importance of irregular antibodies in BMT donors remains unclear, establishment of guidelines for blood product selection might be useful when BMT is planned from a donor with irregular antibodies.

DOI： 10.3925/jjtc.60.483

CiNii Article

researchmap

健常人ドナー末梢血幹細胞採取時における副作用、電解質異常について

藤井敬子, 淺田騰, 藤原英晃, 山川美和, 熊本貴子, 狩山由貴, 池田亮, 浅野尚美, 小郷博昭, 藤井伸治, 岩月啓氏

日本輸血細胞治療学会誌 59 ( 6 ) 865 - 865 2013.12